Gossamer Bio is a San Diego-based biotech that is readying for an initial public offering – and with a diverse pipeline including potential treatments for a severe type of asthma, pulmonary arterial hypertension and inflammatory bowel disease, this IPO could be particularly appealing to investors. However, despite the promise associated with this biotech, there are also a number of potential problems that prospective investors should be aware of. For more, CLICK HERE.
One of the first big Chinese initial public offerings this year is expected to be a Hong Kong-based online brokerage. What makes this IPO particularly interesting for investors, in addition to the company being backed by Chinese conglomerate Tencent, is the fact that the firm is profitable and poised for extraordinary growth from the rise of an affluent Chinese middle class. For more on this IPO to watch, CLICK HERE.
“Think of it like a massive bottleneck or a dam that is ready to explode,” states the author of today’s article of the tidal wave of tech IPOs that he sees coming after two years of very little tech IPO activity. But what caused this bottleneck to occur? The author outlines two new dynamics that have completely changed the way technology companies are financed and taken public – and which may be leading up to what he sees as “the most exciting investment opportunity of our lifetimes.” CLICK HERE to read more.
“Most investors don’t have much – or any – exposure to IPOs (Initial Public Offerings),” acknowledges the author of today’s article before outlining some of the reasons for this. With IPO activity expected to accelerate in the coming months after a major lull in the first half of the year, the author outlines what he believes is the best way for the “little guy” not part of the 1% to play the IPO market – one of two IPO-focused ETFs. For an overview of these two ETFs – including notable holdings, their respective performance since inception and the advantages each has over the other – CLICK HERE.